



uclh

Secretion Management in MND?

Jan Clarke
Consultant Nurse for MND



This Session


- Saliva what is it and how is it produced
- Saliva management in MND
- Medication
- Thick or thin ??
- Complimentary therapy
- The evidence





Saliva

- Extracellular fluid produced and secreted by saliva glands
 - 99.5% Water
 - Electrolytes
 - Mucus
 - White blood cells
 - Enzymes
 - Antimicrobial agents





Role of saliva


- Lubricant
- Aids digestion dilution of starch and sugars
- Taste
- Maintenance of ph of the mouth
- Tooth integrity
- Antibacterial
- Tissue repair
- Aids speech





The salivary glands

- Parotid Watery, serous secretion
- Submandibular Mixed serous and mucous secretion
- Sublingual Mucous secretions




uclh














University College London Hospitals

NHS Foundation Trust





Production of saliva

- Controlled by autonomic NS, mediated by adrenergic and cholinergic nerve endings, primarily under parasympathetic control
- 70% of unstimulated saliva production from submandibular and sublingual glands 20% from parotid 10% from minor secretory glands
- Most stimulated saliva production comes from parotid
- Stimulated flow is 5x greater than unstimulated flow





Parasympathetic control of saliva




Fig 2 - Path of parasympathetic fibres to the parotid gland.

- PSN co-ordinated by centres in medulla
- stimulated by facial & glossopharyngeal nerve
- Stimulation of PSN releases Ach which acts on Muscarinic receptors
- Muscarinic receptors
 - Increase production of saliva
 - Increase blood flow to saliva glands
 - Cause contraction of myoepithlium
 - Increased rate of expulsion of saliva





Muscarinic receptors

- Eyes
- Glandular secretion
- Cardiovascular
- Gl
- Bladder
- Lungs
- CNS





Saliva management in MND

Drooling

- Poor dental hygiene
- Feeding difficulties
- Local skin maceration
- Fluid loss
- Adversely affects self-image
- Leads to poor socialisation
- Increased care needs
- Odour
- Infection





Treatment

- Anticholinergic drugs
- Can be effective but risk of significant side-effects
- Side-effects compounded by common medications; antihistamines, neuroleptics, sedatives
- 20-40% non-compliance
- Cannot be given to patients with glaucoma, obstructive uropathy, gastrointestinal motility problems, myasthenia gravis







Antimuscarinic medication side effects

Eyes pupillary dilatation, blurred vision

Cardiovascular increase in HR

GI Constipation

Bladder Urinary retention

Respiratory bronchodilation and drying of secretions

CNS antiemetic properties

drowsiness

confusion

Reduction in saliva production





NHS Foundation Trust



- Readily absorbed through GI tract and the eye
- Crosses BBB
- Avoid in close angle glaucoma



- Crosses BBB
- Metabolised by liver
- Can be given with poor renal function



- Buscopan
- Doesn't cross BBB



- Scopolamine patches
- Crosses BBB
- Lasts for 72 hours













Glycopyrronium

 The recommended dosage is 0.02 mg/kg 3 times daily initially, with doses titrated in increments of 0.02 mg/kg every 5–7 days based on therapeutic response and adverse effects.

- The maximum recommended dose is 0.1 mg/kg 3 times daily (not to exceed 1.5 to 3 mg per dose based on weight).
- Doses should be given at least 1 hour before, or 2 hours after, meals.

NICE; Hypersalivation: oral glycopyrronium bromide Evidence summary [ESUOM15] Published date: July 2013





Carbocisteine

- Mucolytic agent
- Rapidly absorbed from GI tract
- 375mg / qds



- The combination of mucolytics with antitussives and/or substances that dry out secretions (atropinic) is not rational
- https://www.medicines.org.uk/emc/2019





Botulinum Toxin

- First recorded In 1822
- Botox binds selectively to cholinergic nerve terminals at presynaptic membrane
- It inhibits ACh release, reduced function of parasympathetic controlled endocrine glands

 Blockade is irreversible but temporary



Estimated cost of £2.4k/patient/year (Hertfordshire Medicines Management Committee – Sept 2012)





NHS Foundation Trust





Motor neurone disease: assessment and management

NICE guideline Published: 24 February 2016 www.nice.org.uk/guidance/ng42

© NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated 23 July 2019



A or B?

Botulinum Toxin A Versus B in Sialorrhea: A Prospective, Randomized, Double-Blind, Crossover Pilot Study in Patients with Amyotrophic Lateral Sclerosis or Parkinson's Disease

Arianna Guidubaldi, MD,¹ Alfonso Fasano, MD,¹ Tamara Ialongo, MD, PhD,¹ Carla Piano, MD,¹ Maurizio Pompili, MD, PhD,² Roberta Mascianà, MD,² Luisa Siciliani, MD,² Mario Sabatelli, MD, PhD,¹ and Anna Rita Bentivoglio, MD, PhD^{1*}

1 Istituto di Neurologia, Università Cattolica del Sacro Cuore, Roma, Italia

2 Istituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore, Roma, Italia

Movement Disorders p313-319 Vol. 26, No.2, 2011





Not for everyone?

- Pro
 - Effect lasts for 8-12 weeks
 - Reduces the need for administration of medication
 - Good for people who live alone
 - Easy to administer in clinic

- Cons
- Lasts for 8-12 weeks
- Temporarily irreversible
- Needs access to hospital to administer
- Difficult to access at end of life?
- May make secretions thicker?



Radiotherapy

- Local irradiation of the parotid gland
- Xerostomia, dental caries, hyperpigmentation, burns, mucositis
- Malignancy 10-15 years post-treatment
- Restricted to elderly with severe drooling where surgery is not an option and medication is contraindicated











Thick Saliva

- Hydrate
- Avoid caffeine and alcohol
- Humidification / saline nebulisers
- Suck on crushed ice
- Carbocycteine
- Introduce beta-blocker if associated with excess secretions





Thin Saliva

- Postural changes
- Support collars
- Anticholinergic mediation

Ease of administration

Frequency needed

Half life


Side effects


Access to therapy





Complimentary therapy









- Kali Bi
 - Action on mucous membranes
 - Thick, stringy yellow or white secretions
 - Pan-sinusitis
 - Nausea and vomiting of stringy mucous







Hedera Helix

- Spasmodic cough
- Acute and chronic inflammatory bronchial disease
- Reduces bronchial mucous





Pelargonium= Umckaloabo

- South African medicinal plant
- Pelargonium root extract
- Works against viruses and bacteria
- Is expectorant
- For the treatment of acute bronchitis
- Infect blocker, also prophylactic





Ginger

- Ginger increases salivation, gastric juice production, bile flow and intestinal peristalsis.
- Ginger tea is also drunk on coughs and colds. It is likely to have a mucolytic effect in these cases because of the pungent taste.
- Good for loss of appetite, bloating and flatulence.





- Turmeric (Herb, Ingredient of Curry)
 - Strengthens immune system
 - Inhibits inflammation
 - Strong anti-oxidative effect
 - Supports the liver during detoxification
 - Concentrated feed for the cells





- Papain Enzyme
 - Breaks now protein in mucous
 - Found in papaya and pineapple











University College London Hospitals

NHS Foundation Trust

Evidence?

Taylor & Francis



Cochrane Database of Systematic Reviews

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis (Review)

Young CA, Ellis C, Johnson J, Sathasivam S, Pih N



Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

ISSN: 2167-8421 (Print) 2167-9223 (Online) Journal homepage: http://www.tandfonline.com/loi/iafd20

Developing an outcome measure for excessive saliva management in MND and an evaluation of saliva burden in Sheffield

Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis Harriman, Maureen; Morrison, Murray; Hay, John; Ravonta, Matti; et al

The Journal of Otolaryngology; Aug 2001; 30, 4; ProQuest pg. 242

AUTHORS' CONCLUSIONS

Implications for practice

There is extremely limited evidence from randomized controlled trials about treatments to reduce sialorrhea in MND. The well designed trial on botulinum toxin type B injected into parotid and submandibular glands showed beneficial effects for four or more weeks (Jackson 2009).

Implications for research

There is a need for considerable further work on treating this dis-

RESEARCH ARTICLE

Botulinum Toxin A Versus B in Sialorrhea: A Prospective, Randomized, Double-Blind, Crossover Pilot Study in Patients with Amyotrophic Lateral Sclerosis or Parkinson's Disease

Arianna Guidubaldi, MD, 1 Alfonso Fasano, MD, 1 Tamara lalongo, MD, PhD, 1 Carla Piano, MD, 1 Maurizio Pompili, MD, PhD, 2 Roberta Mascianà, MD.² Luisa Siciliani, MD.² Mario Sabatelli, MD. PhD.¹ and Anna Rita Bentivoglio, MD. PhD¹ ¹Istituto di Neurologia, Università Cattolica del Sacro Cuore, Roma, Italia

²Istituto di Medicina Interna e Geriatria, Università Cattolica del Sacro Cuore, Floma, Italia

Vol. 23 No. 1 January 2002

Nebulized Glycopyrrolate for Drooling in a Motor Neuron Patient


To the Editor:

Sialorrhea and drooling are common problems for patients with motor neuron disease (MND). About 40% of patients are troubled by mented an improvement in both the sialorrhea and drooling in the case notes.

The same regimen was continued for two months with good symptom control, but she then developed a rash around her mouth. It was erythematous, maculopapular and pruritic in nature. She was evaluated by a dermatologist who thought the nebulizer was potentially responsi-







Step wise algorithm to treatment of sialorrhea in **MND**

NHS Foundation Trust

Clarke J



